Loading clinical trials...
Loading clinical trials...
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
Conditions
Interventions
Bintrafusp alfa
Locations
12
United States
GSK Investigational Site
Lake Success, New York, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Poitiers, France
GSK Investigational Site
Toulouse, France
Start Date
October 15, 2020
Primary Completion Date
August 15, 2022
Completion Date
August 15, 2022
Last Updated
April 18, 2024
NCT03206060
NCT06608446
NCT07541924
NCT07542041
NCT00033137
NCT04389632
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions